RABIES CASE PRESENTATION Medical Center Hospital September 8 th , - - PowerPoint PPT Presentation

rabies case presentation
SMART_READER_LITE
LIVE PREVIEW

RABIES CASE PRESENTATION Medical Center Hospital September 8 th , - - PowerPoint PPT Presentation

Michelle Aguirre, PharmD RABIES CASE PRESENTATION Medical Center Hospital September 8 th , 2017 PART I: CASE INTRODUCTION AND Michelle Aguirre, PharmD Medical Center Hospital DISEASE OVERVIEW September 8 th , 2017 CASE INTRODUCTION Chief


slide-1
SLIDE 1

RABIES CASE PRESENTATION

Michelle Aguirre, PharmD Medical Center Hospital September 8th, 2017

slide-2
SLIDE 2

PART I: CASE INTRODUCTION AND DISEASE OVERVIEW

Michelle Aguirre, PharmD Medical Center Hospital September 8th, 2017

slide-3
SLIDE 3

CASE INTRODUCTION

Chief complaint  Unobtainable at the moment History of present illness  JC is a 49-year-old male who was walking down the street and was drinking one liter of vodka roaming exhibiting signs of confusion. He was called by his neighbor to go back to his house, as it was hot in the day. The patient refused to go back to this home and had recurrent falls on his head and sustained multiple injuries on his limbs and left knee. Along his journey, a dog came and bit him on his left knee and then ran away. Afterwards, one of the neighbors called the ambulance and the patient was transferred to the ER for further care.

slide-4
SLIDE 4

CASE INTRODUCTION

PMH

 Hypertension  Bipolar disorder  Chronic active alcoholism

Family history

 Unknown

Social history

 Drinks about one liter of vodka every day for the last 20 years and has multiple admissions for alcohol withdrawal symptoms

Allergies

 Sulfa (reaction unknown)

Home Medications

 Seroquel 400 mg PO daily  Lithium 300 mg PO TID  Lisinopril 20 mg PO daily

slide-5
SLIDE 5

CASE INTRODUCTION

Review of systems:

 General appearance: Patient was awake and alert and in severe acute distress  Head: Normocephalic. No raccoon’s eyes or battle signs  Neck: Mild tenderness in the upper cervical spine/posterior scalp  Eyes: PERRLA, extraocular muscles intact  Respiratory: Lungs clear to auscultation bilaterally, no respiratory distress  Cardiovascular: Regular rate and rhythm, no murmurs, rubs, or gallops  Abdomen: Soft, nontender, nondistended  Neuro: GCS 15, awake alert, and oriented x4  Skin: Multiple bruises noted from patient’s posterior shoulder to his right flank; There is a large bruise over the patient’s left knee with good range of motion. Also, presence of dog bite with minor skin abrasions  Extremities: Left knee bruise, normal range of motion

slide-6
SLIDE 6

CASE INTRODUCTION

Vital Signs HR: 77 RR: 13 BP: 58/25 Temp: 101F Weight: 91kg Height: 6’6’’ Labs

Na 129 L Glucose 76 WBC 14.8 H K 4.0 Mg Hgb 9.2 Cl 75 L Albumin 3.6 Plts 124 L CO2 16 L AST 42 H

  • Lact. Acid 3.1

H BUN 112 H ALT 38 PT 18.0 H SCr 20.6 H Bili 0.9 INR 1.53 H

slide-7
SLIDE 7

CASE INTRODUCTION

JC is admitted to the ICU where the admitting physician decides to start this patient on a rabies vaccine schedule The whole ICU team is now on the case and will follow the patient clinically and make adjustments as necessary

slide-8
SLIDE 8

RABIES: BACKGROUND

Rabies is a zoonotic disease caused by RNA viruses in the family Rhabdoviridae, genus Lyssavirus Virus is transmitted in the saliva of rabid mammals via a bite After entry to the central nervous system, these viruses cause an acute progressive encephalomyelitis The incubation period usually ranges from 1 to 3 months after exposure, but can range from days to years The vast majority of rabies cases reported to the Centers for Disease Control and Prevention (CDC) each year occur in wild animals like raccoons, skunks, bats, and foxes

slide-9
SLIDE 9

EPIDEMIOLOGY

Over the last 100 years, rabies in the United States has changed dramatically More than 90% of all animal cases reported annually to CDC now

  • ccur in wildlife (before 1960, the majority were domestic animals)

The principal rabies hosts today are wild carnivores and bats The number of rabies-related human deaths in the United states has declined from more than 100 annually at the turn of the century to

  • ne or two per year in the 1990’s

Prompt wound care and the administration of rabies immune globulin (RIG) and vaccine are highly effective in preventing human rabies following exposure

slide-10
SLIDE 10

TRANSMISSION

The route of infection is usually, but not necessarily, by a bite In many cases the affected animal is exceptionally aggressive, may attack without provocation, and exhibits otherwise uncharacteristic behavior Transmission may also occur via an aerosol through mucous membranes (transmission in this form may have happened in people exploring caves populated by rabid bats) Transmission between humans is extremely rare, although it can happen through transplant surgery, or, eve, more rarely through bites

  • r kisses

Various routes of transmission have been documented and include contamination of mucous membranes (i.e., eyes, nose mouth), aerosol transmission, and corneal transplantations

slide-11
SLIDE 11

PATHOPHYSIOLOGY: OVERVIEW

Infection by bite

  • The virus directly or indirectly enters the peripheral nervous system
  • It then travels along the nerves towards the central nervous system

Virus reaches brain

  • Rapid encephalitis develops and symptoms appear
  • The spinal cord may inflame producing myelitis

Perivascular infiltration

  • Lymphocytes, polymorphonuclear leukocytes, and plasma cells may

leak throughout the entire CNS

  • Virus enters salivary glands and other organs of victim

Am J Vet Res. 1966 Jan;27(116):24-32

slide-12
SLIDE 12

SIGNS AND SYMPTOMS

When a person contracts rabies, they do not show symptoms immediately The disease takes a period of time to manifest in the body which is known as its period of incubation Once symptoms arise, the patients condition deteriorates rapidly

slide-13
SLIDE 13

FIVE STAGES OF RABIES

Incubation period: 5 days to > 2 years U.S. median ~ 35 days Pro-dome State: 0-10 days Early flu-like symptoms Acute neurologic period: 2-7 days Neurologic symptoms begin Coma: 5-14 days Requires mechanical ventilation Death

slide-14
SLIDE 14

SIGNS AND SYMPTOMS

*Death usually occurs within day of the onset of late symptoms

Early Symptoms Late Symptoms

  • Fever
  • Headache
  • Generalized weakness
  • Generalized discomfort
  • Insomnia
  • Anxiety
  • Confusion
  • Slight or partial paralysis
  • Excitation
  • Hallucinations
  • Agitation
  • Hypersalivation
  • Difficulty swallowing
  • Hydrophobia
slide-15
SLIDE 15

DIAGNOSIS

In animals, rabies is diagnosed using the direct fluorescent antibody (DFA) test, which looks for the presence of rabies virus antigens in brain tissue Several tests are required in humans to diagnose rabies ante-mortem (before death); no single test is sufficient Saliva can be tested by virus isolation or reverse transcription followed by polymerase chain reaction (RT-PCR) Serum and spinal fluid are tested for antibodies to rabies virus Skin biopsy specimens are examined for rabies antigen in the cutaneous nerves at the base of hair follicles

slide-16
SLIDE 16

PART II: DRUG THERAPY DISCUSSION

Schizophrenia Final Presentation Michelle Aguirre, PharmD Candidate 2017

slide-17
SLIDE 17

EARLY MANAGEMENT

Wash any wounds immediately

 One of the most effective ways to decrease the chance for infection is to wash the wound thoroughly with soap and water

Refer to a doctor

 For attention for any trauma due to the animal attack before considering the need for rabies vaccination  The doctor, possibly in consultation with state or local health department, will decide on the need of rabies vaccination  Decisions to start vaccination, known as post-exposure prophylaxis (PEP) are up to the discretion of the physician, but two organizations have developed recommendations:

 Advisory Committee on Immunization Practices (ACIP) schedule for rabies vaccine (2010)  World Health Organization (WHO) pre- and post-exposure prophylaxis 2010

slide-18
SLIDE 18

EARLY MANAGEMENT

Post-exposure prophylaxis (PEP)

 CDC recommends following ACIP 2010 vaccination schedule  Consists of one dose of immune globulin and four doses of rabies vaccine over a 14- day period  Rabies immune globulin and the first dose of rabies vaccine should be given by a health care provider as soon as possible after exposure  Additional doses or rabies vaccine should be given on days 3, 7, and 14 after the first vaccination  Current vaccines are relatively painless and are given in the arm, like a flu vaccine  Rabies immunoglobulin is referred to as “passive immunization” while rabies vaccine is referred to as “active immunization” *Recommendations for PEP schedules are based on vaccination status: not previously vaccinated vs. previously vaccinated*

slide-19
SLIDE 19

POST-EXPOSURE PROPHYLAXIS

Goal: To neutralize the virus at the site of infection before it can enter the human nervous system  generally ensures survival Rabies Immune Globulin

 The administration of RIG provides immediate virus-neutralizing antibodies until protective antibodies are generated in response to vaccine  HRIG has a half-life of approximately three weeks  Two preparations of HRIG are licensed and available in the U.S.

Rabies Vaccines

 Rabies vaccine induces the production for protective virus-neutralizing antibodies within approximately 7 to 10 days that persist for several years  Two licensed vaccines are currently available in the U.S.

slide-20
SLIDE 20

DYNAMICS OF RABIES AND PEP

Figure 1. Schematic of dynamics of rabies virus pathogenesis in the presence and absence of PEP-mediated immune responses

slide-21
SLIDE 21

NOT PREVIOUSLY VACCINATED

Intervention Regimen Wound cleansing All PEP should begin with immediate thorough cleansing of all wounds with soap and water. If available, a virucidal agent (e.g., povidine-iodine solution) should be used to irrigate the wounds Human rabies immune globulin (HRIG) Administer 20 IU/kg body weight on day 0. If anatomically feasible, the full dose should be infiltrated around and into the wound(s), and any remaining volume should be administered intramuscularly at an anatomical site distant from the vaccine administration Vaccine Human diploid cell vaccine (HDCV) or purified chick embryo cell vaccine (PCECV) 1.0 mL, IM (deltoid area), 1 each on days 0, 3, 7 and 14

slide-22
SLIDE 22

PREVIOUSLY VACCINATED

Intervention Regimen Wound cleansing All PEP should begin with immediate thorough cleansing of all wounds with soap and water. If available, a virucidal agent (e.g., povidine-iodine solution) should be used to irrigate the wounds Human rabies immune globulin (HRIG) HRIG should not be administered Vaccine Human diploid cell vaccine (HDCV) or purified chick embryo cell vaccine (PCECV) 1.0 mL, IM (deltoid area), 1 each on days 0 and 3

slide-23
SLIDE 23

POST-EXPOSURE PROPHYLAXIS FOR UNVACCINATED PERSONS

1. The combination of RIG and vaccine is recommended for both bite and non-bite exposures, regardless of the time interval between exposure and initiation of PEP 2. If PEP has been initiated and appropriate laboratory diagnostic testing (i.e., the direct fluorescent antibody test) indicates that the animal that caused the exposure was not rabid, PEP may be discontinued 3. If HRIG was not administered when vaccination was begun on day 0, it can be administered up to and including day 7 of the PEP series 4. Even when PEP is administered imperfectly or not according to the schedule, it might generally be effective

slide-24
SLIDE 24

OTHER KEY POINTS

HRIG is not administered in the same syringe or at the same anatomic site as the first vaccine dose The gluteal area should not be used because administration of vaccine in this area may result in diminished immunologic response Children should receive the same vaccine dose (i.e., vaccine volume) as recommended for adults

slide-25
SLIDE 25

SEROLOGIC TESTING

All healthy persons tested in accordance with ACIP guidelines after completion of at least a 4-dose regimen of rabies PEP should demonstrate an adequate antibody response against rabies virus No routine testing of healthy patients completing PEP is necessary to document seroconversion When titers are obtained, serum specimens collected 1-2 weeks after prophylaxis should completely neutralize challenge virus The titers will decline gradually since the last vaccination

slide-26
SLIDE 26

ADVERSE REACTIONS AND PRECAUTIONS

Adverse effects with modern human rabies vaccination are uncommon Pregnancy and infancy are not contraindications Immunosuppression

 All rabies vaccines licensed in the United States are inactivated cell-culture vaccines that can be administered safely to persons with altered immunocompetence  Use of corticosteroids, other immunosuppressive agents, antimalarials, and immunosuppressive illnesses might reduce immune responses to rabies vaccines and should receive a 5-dose vaccine regimen

slide-27
SLIDE 27

PRICING AND AVAILABILITY

Rabies Immune Globulin Injection (HyperRAB S/D Intramuscular)

 150 units/mL (2mL): $852.14

Injection (Imogam Rabies-HT Intramuscular)

 150 units/mL (2mL): $867.05

Rabies Virus Vaccine Injection (Imovax Rabies Intramuscular)

 2.5 units/mL (1): $386.76

Location at Medical Center Hospital Immunoglobulin is stored in Gloria’s office in the first refrigerator Vaccines are dispensed from the central pharmacy

slide-28
SLIDE 28

WHO VACCINE RECOMMENDATIONS

Definition of categories of exposure and use of rabies biologicals from the World Health Organization (2010)

Immune globulin + vaccine

Transdermal bites or scratches, licks on broken skin, contamination of mucous membrane with saliva, or contact with bats

Vaccine

  • nly

Minor scratches or abrasions without bleeding or and nibbling of uncovered skin

No prophylaxis

Touching, feeding of animals, or licks on intact skin

slide-29
SLIDE 29

INFECTIOUS DISEASES SOCIETY OF AMERICA

Therapy Recommendation Post-exposure prophylaxis

  • May be indicated; consultation with local health officials

is recommended to determine if vaccination should be initiated

Skin and Soft Tissue Infection Guidelines (2014)

 Specific recommendations are made for dog bites, including indications for antimicrobials  IDSA briefly mention PEP in their guidelines

slide-30
SLIDE 30

PART III: CLINICAL COURSE

Michelle Aguirre, PharmD Candidate 2017

slide-31
SLIDE 31

CLINICAL COURSE

Day 1: JC received the following regimen on day 0:

 No documentation of wound care was found  Dog that bit patient was presumably killed by neighbor who owned dog

slide-32
SLIDE 32

CLINICAL COURSE

Was this treatment appropriate?

 Correct treatment The recommendation is to administer: Immune globulin 20 IU/kg x 91 kg = ~18,000 units Chick embryo cell vaccine 2.5 mL/mL x 2.5 mg = 1 mL Both should be given intramuscularly on day 0! However, we do not know if he received proper wound care…

slide-33
SLIDE 33

CLINICAL COURSE

Days that followed: Is this regimen appropriate?

Day 0 RIG and vaccine 1 1 mL Day 4 Vaccine 2 1 mL Day 7 Vaccine 3 1 mL Day 12 Patient discharged Day 14 Scheduled vaccine never given

slide-34
SLIDE 34

PATIENT COURSE CONCLUSION

 JC received the correct doses for RIG and vaccines  ACIP recommends immune globulin + vaccines (CDC preferred); WHO classification is difficult to determine but likely recommends vaccine only for this patient  Wound care was never documented in the patient chart ± Although the treatment plan did not follow the vaccine schedule days exactly and the patient did not receive the last vaccine, he is expected to have some general immunity

slide-35
SLIDE 35

QUESTIONS?

slide-36
SLIDE 36

REFERENCES

1.

  • CDC. Rabies. Centers for Disease Control and Prevention [cited

September 1, 2017]. Available from [https://www.cdc.gov/rabies/index.html]. 2.

  • CDC. Rabies prevention – Unites States, 2010: recommendations
  • f the Immunization Practices Advisory Committee (ACIP). Y40(No.

RRR-3) 3. Dietzschold B, Schnell M, Koprowski H. Pathogenesis of rabies. Curr Top Microbiol Immunol. 2005;292:45-56. 4. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):147-59.